LifeVantage Co. (NASDAQ:LFVN) Sees Significant Drop in Short Interest

LifeVantage Co. (NASDAQ:LFVNGet Free Report) saw a significant decline in short interest in January. As of January 15th, there was short interest totalling 101,900 shares, a decline of 5.1% from the December 31st total of 107,400 shares. Based on an average daily volume of 55,800 shares, the days-to-cover ratio is presently 1.8 days. Approximately 1.0% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Separately, began coverage on LifeVantage in a research note on Thursday, October 5th. They issued a “strong-buy” rating for the company.

View Our Latest Report on LifeVantage

Insider Activity

In other news, Director Michael A. Beindorff sold 5,500 shares of the company’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $6.00, for a total value of $33,000.00. Following the sale, the director now directly owns 54,798 shares in the company, valued at $328,788. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 6.76% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Ritholtz Wealth Management acquired a new position in shares of LifeVantage in the 3rd quarter worth approximately $131,000. O Shaughnessy Asset Management LLC acquired a new position in LifeVantage during the 2nd quarter valued at approximately $90,000. EA Series Trust acquired a new position in LifeVantage during the 2nd quarter valued at approximately $256,000. Carlsbad Wealth Advisory Group Inc. acquired a new position in LifeVantage during the 2nd quarter valued at approximately $63,000. Finally, EP Wealth Advisors LLC acquired a new position in LifeVantage during the 1st quarter valued at approximately $234,000. Hedge funds and other institutional investors own 35.66% of the company’s stock.

LifeVantage Price Performance

Shares of NASDAQ:LFVN opened at $5.31 on Thursday. The firm has a market capitalization of $67.49 million, a PE ratio of 26.55 and a beta of 0.76. The business has a 50-day moving average of $6.06 and a two-hundred day moving average of $6.15. LifeVantage has a 12 month low of $3.04 and a 12 month high of $8.69.

LifeVantage (NASDAQ:LFVNGet Free Report) last issued its earnings results on Thursday, November 9th. The company reported $0.13 earnings per share for the quarter. LifeVantage had a return on equity of 12.47% and a net margin of 1.20%. The company had revenue of $51.36 million during the quarter.

LifeVantage Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, December 15th. Investors of record on Friday, December 1st were issued a $0.035 dividend. This represents a $0.14 dividend on an annualized basis and a yield of 2.64%. The ex-dividend date of this dividend was Thursday, November 30th. LifeVantage’s dividend payout ratio is currently 70.00%.

About LifeVantage

(Get Free Report)

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.

Recommended Stories

Receive News & Ratings for LifeVantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeVantage and related companies with's FREE daily email newsletter.